Forxiga Consumer Information - AstraZeneca
Product Monograph Master Template Template date: September 2020 FORXIGA (dapagliflozin propanediol monohydrate) Page 3 of 8 COPYRIGHT 2014-2021 ASTRAZENECA CANADA INC FORXIGA and when to start taking it again. have a sudden reduction in your insulin dose have a history of DKA. • are older than 65 years of age
Download Forxiga Consumer Information - AstraZeneca
Information
Domain:
Source:
Link to this page:
Documents from same domain
PRODUCT MONOGRAPH INCLUDING PATIENT …
www.astrazeneca.caINCLUDING PATIENT MEDICATION INFORMATION LYNPARZA ... including long-term survival follow-up, and the majority of events had a fataloutcome. All patients had potential contributing factors for the development of MDS/AML, having received
INCLUDING PATIENT MEDICATION INFORMATION
www.astrazeneca.caother information relevant to the use of the drug. Patients should be advised to contact their healthcare provider immediately to report any new chest pain or discomfort, changes in
PRODUCT MONOGRAPH SYMBICORT …
www.astrazeneca.caindicated for the maintenance treatment of moderate to severe COPD including chronic bronchitis and emphysema, in patients with persistent symptoms and a history of exacerbations, where the use of a combination product is considered appropriate. SYMBICORTTURBUHALER is NOT indicated for the relief of acute bronchospasm in COPD patients.
PRODUCT MONOGRAPH INCLUDING PATIENT …
www.astrazeneca.caProduct Monograph Master Template Template date: September 2020 FORXIGA (dapagliflozin propanediol monohydrate) Page 1of 75 COPYRIGHT 2014-2021 ASTRAZENECA CANADA INC PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION FORXIGA® Dapagliflozin propanediol monohydrate Tablets, 5 mg and 10 mg, Oral ATC Code: A10BK01
Related documents
MATERIAL SAFETY DATA SHEET 1. Product and Company ...
www.rbnainfo.comMar 26, 2010 · Isopropanol 67-63-0 Monograph 71 [1999]; Supplement 7 [1987]; Monograph 15 [1977] Carcinogenicity The finished product is not expected to have chronic health effects. space Mutagenicity The finished product is not expected to have chronic health effects. space Reproductive effects The finished product is not expected to have chronic health ...
PRODUCT MONOGRAPH
pdf.hres.caPRODUCT MONOGRAPH DUKORAL® Oral, Inactivated Cholera and ETEC Diarrhea Vaccine Oral Suspension Active Immunizing Agent for the Prevention of Diarrhea Caused by Vibrio cholerae and/or heat-labile toxin producing Enterotoxigenic Escherichia coli ATC Code: J07AE01 Manufactured by: Date of Approval: Valneva Sweden AB,
PRODUCT MONOGRAPH
pdf.hres.caPRODUCT MONOGRAPH Pr WELLBUTRIN ... PART III: CONSUMER INFORMATION ... symptoms including delusions, hallucinations, psychosis, concentration disturbance, paranoia and confusion. In some cases these abated upon dose reduction and/or withdrawal of treatment.
Fluzone High Dose - Sanofi
products.sanofi.caSanofi Pasteur Product Monograph 372 - FLUZONE® High-Dose Page 3 of 23 FLUZONE® High-Dose Influenza Virus Vaccine Trivalent Types A and B (Split Virion) PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration: Intramuscular injection. Dosage Form/Strength: Suspension for injection. Active …
PRODUCT MONOGRAPH SYMBICORT …
www.astrazeneca.caindicated for the maintenance treatment of moderate to severe COPD including chronic bronchitis and emphysema, in patients with persistent symptoms and a history of exacerbations, where the use of a combination product is considered appropriate. SYMBICORTTURBUHALER is NOT indicated for the relief of acute bronchospasm in COPD patients.
PART III: CONSUMER INFORMATION INSPIOLTO RESPIMAT …
www.boehringer-ingelheim.caInspiolto® Respimat ® Product Monograph Page 43 of 50 PART III: CONSUMER INFORMATION ... CONSUMER INFORMATION . ... including drugs prescribed by other doctors, vitamins, minerals, natural supplements, or alternative medicines. ...
PRODUCT MONOGRAPH - Pfizer Canada
www.pfizer.caPrevnar® 13 (Pneumococcal 13-valent Conjugate Vaccine) Product Monograph Page 7of 61 3. Adults 18Years and Older Safety was assessed in 7 clinical studies including 91,593 adults ranging in ages from 18 to 101 years. Prevnar 13 was administered to 48,806 adults; 2,616 adults were aged 50-64 years and 45,291 adults were 65 years and older.
Labeling <7> Type of Posting Posting Date Official Date ...
www.uspnf.comAug 30, 2019 · , Monograph Naming Policy for Salt Drug Substances in Drug Products and Compounded Preparations). Labeling The labeling clearly states the specific salt form of the active moiety that is present in the product or preparation because this information may be useful to practitioners and patients. The names and strengths of both the active moiety ...